Anika Therapeutics Inc Financials
Anika Therapeutics Inc (ANIK) reported $120.7M in revenue over the twelve months to Jun 30, 2026, up 5.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Anika’s current story is cash recovery without sales recovery, while core operating economics remain under pressure.
The apparent profit rebound in FY2025 is less dramatic than the net-income line suggests: net loss narrowed from-$56.0M to-$11.0M . At the same time, operating loss widened from-$5.1M to-$11.1M , so the year looked better mainly because FY2024 carried heavier below-operating-line damage, not because the core business had returned to profitability.
What changed inside the business was earnings quality: operating cash flow reached
The deeper operating concern is gross-margin compression, not just overhead discipline: gross margin slid from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Anika Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Anika Therapeutics Inc scores 4.98, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($282.4M) relative to total liabilities ($46.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Anika Therapeutics Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Anika Therapeutics Inc reported a net loss of $11.0M while generating $11.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Anika Therapeutics Inc generated $112.8M in revenue in fiscal year 2025. This represents a decrease of 5.9% from the prior year.
Anika Therapeutics Inc's EBITDA was -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 418.5% from the prior year.
Anika Therapeutics Inc reported -$11.0M in net income in fiscal year 2025. This represents an increase of 80.4% from the prior year.
Anika Therapeutics Inc earned -$0.76 per diluted share (EPS) in fiscal year 2025. This represents an increase of 80.2% from the prior year.
Cash & Balance Sheet
Anika Therapeutics Inc generated $4.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 287.1% from the prior year.
Anika Therapeutics Inc held $57.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Anika Therapeutics Inc's gross margin was 56.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 6.8 percentage points from the prior year.
Anika Therapeutics Inc's operating margin was -9.8% in fiscal year 2025, reflecting core business profitability. This is down 5.5 percentage points from the prior year.
Anika Therapeutics Inc's net profit margin was -9.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 37.0 percentage points from the prior year.
Anika Therapeutics Inc's ROE was -7.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 28.7 percentage points from the prior year.
Capital Allocation
Anika Therapeutics Inc invested $25.8M in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
Anika Therapeutics Inc spent $9.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 13.1% from the prior year.
Anika Therapeutics Inc invested $6.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.7% from the prior year.
ANIK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.6M+10.1% | $29.6M-3.3% | $30.6M+10.1% | $27.8M-1.4% | $28.2M+7.8% | $26.2M-14.5% | $30.6M+3.5% | $29.6M |
| Cost of Revenue | $11.4M+7.1% | $10.6M-7.2% | $11.4M-6.5% | $12.2M-11.7% | $13.9M+20.6% | $11.5M-14.8% | $13.5M+32.8% | $10.2M |
| Gross Profit | $21.2M+11.8% | $19.0M-0.9% | $19.2M+23.1% | $15.6M+8.5% | $14.4M-2.2% | $14.7M-14.3% | $17.1M-11.8% | $19.4M |
| R&D Expenses | $7.3M+9.4% | $6.7M+4.0% | $6.5M-7.1% | $6.9M+10.0% | $6.3M+4.2% | $6.1M-6.9% | $6.5M+9.4% | $5.9M |
| SG&A Expenses | $10.9M-38.4% | $17.8M+47.1% | $12.1M+1.8% | $11.9M-2.9% | $12.2M-5.2% | $12.9M+14.0% | $11.3M-16.4% | $13.5M |
| Operating Income | $3.0M+153.8% | -$5.5M-949.5% | $646K+120.0% | -$3.2M+22.7% | -$4.2M+2.4% | -$4.3M-507.7% | -$705K-770.4% | -$81K |
| Income Tax | $71K-69.8% | $235K+122.7% | -$1.0M-210.4% | $939K+37.9% | $681K+665.2% | $89K-96.5% | $2.5M+16.4% | $2.2M |
| Net Income | $3.3M+165.4% | -$5.1M-3039.5% | $172K+107.4% | -$2.3M+41.3% | -$4.0M+18.5% | -$4.9M+77.3% | -$21.5M+28.2% | -$29.9M |
| EPS (Diluted) | $0.24+164.9% | -$0.37 | $0.02 | -$0.16+42.9% | -$0.28+17.6% | -$0.34+77.2% | -$1.49+26.6% | -$2.03 |
Not reported in any period shown, so not listed: Interest Expense.
ANIK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $183.5M+2.3% | $179.4M-5.7% | $190.3M+0.4% | $189.4M+0.9% | $187.7M-1.5% | $190.6M-6.0% | $202.7M-12.4% | $231.4M |
| Current Assets | $99.2M+6.0% | $93.6M-9.5% | $103.4M+1.7% | $101.6M+2.3% | $99.3M-3.1% | $102.5M-9.8% | $113.7M-16.5% | $136.1M |
| Cash & Equivalents | $38.4M-6.4% | $41.0M-28.6% | $57.5M-0.9% | $58.0M+9.1% | $53.2M-0.4% | $53.4M-4.1% | $55.6M-10.8% | $62.4M |
| Inventory | $28.6M+25.1% | $22.8M+21.6% | $18.8M+15.4% | $16.3M-3.8% | $16.9M-20.7% | $21.3M-10.4% | $23.8M-39.9% | $39.6M |
| Accounts Receivable | $29.1M+12.8% | $25.8M+8.8% | $23.7M+6.8% | $22.2M-7.4% | $24.0M+9.0% | $22.0M-6.8% | $23.6M-16.8% | $28.4M |
| Goodwill | $7.8M-0.8% | $7.9M-2.0% | $8.1M0.0% | $8.1M-0.1% | $8.1M+8.5% | $7.4M+4.2% | $7.1M-6.9% | $7.7M |
| Total Liabilities | $46.2M+1.6% | $45.5M-2.8% | $46.8M+9.8% | $42.6M+6.6% | $40.0M-5.2% | $42.2M-13.4% | $48.8M-5.4% | $51.5M |
| Current Liabilities | $22.1M+5.6% | $21.0M-4.3% | $21.9M+14.8% | $19.1M+18.7% | $16.1M-10.2% | $17.9M-23.2% | $23.3M-8.6% | $25.5M |
| Total Equity | $137.3M+2.5% | $133.9M-6.7% | $143.5M-2.3% | $146.8M-0.6% | $147.7M-0.5% | $148.4M-3.6% | $154.0M-14.4% | $179.9M |
| Retained Earnings | $59.0M+5.9% | $55.7M-8.3% | $60.8M+0.5% | $60.5M-3.7% | $62.8M-5.9% | $66.8M-6.8% | $71.7M-23.4% | $93.5M |
Not reported in any period shown, so not listed: Long-Term Debt.
ANIK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$684K+85.9% | -$4.8M-204.5% | $4.6M-32.5% | $6.9M+3734.9% | -$189K-45.4% | -$130K-108.2% | $1.6M-68.5% | $5.0M |
| Capital Expenditures | $1.4M+1.3% | $1.4M+120.8% | $648K-65.7% | $1.9M+28.6% | $1.5M-48.1% | $2.8M+116.1% | $1.3M+7.5% | $1.2M |
| Free Cash Flow | -$2.1M+66.0% | -$6.3M-257.4% | $4.0M-19.9% | $5.0M+400.9% | -$1.7M+43.9% | -$3.0M-1174.2% | $275K-92.8% | $3.8M |
| Investing Cash Flow | -$1.3M-3.3% | -$1.2M-725.8% | $198K+111.4% | -$1.7M-221.3% | -$539K-132.2% | $1.7M+227.9% | -$1.3M+28.0% | -$1.8M |
| Financing Cash Flow | -$701K+93.2% | -$10.3M-96.0% | -$5.3M-40507.7% | -$13K-107.3% | $179K+103.3% | -$5.4M-1.6% | -$5.4M-34.2% | -$4.0M |
| Share Buybacks | $853K-90.2% | $8.7M+57.6% | $5.5M | $0 | $0-100.0% | $4.0M-28.8% | $5.6M+40.5% | $4.0M |
Not reported in any period shown, so not listed: Dividends Paid.
ANIK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.1%+1.0pp | 64.1%+1.5pp | 62.6%+6.6pp | 56.0%+5.1pp | 50.9%-5.2pp | 56.1%+0.1pp | 56.0%-9.7pp | 65.7% |
| Operating Margin | 9.1%+27.6pp | -18.5%-20.6pp | 2.1%+13.7pp | -11.6%+3.2pp | -14.8%+1.6pp | -16.4%-14.1pp | -2.3%-2.0pp | -0.3% |
| Net Margin | 10.2%+27.2pp | -17.1%-17.6pp | 0.6%+8.9pp | -8.4%+5.7pp | -14.1%+4.6pp | -18.6%+51.6pp | -70.2% | -101.2% |
| Return on Equity | 2.4%+6.2pp | -3.8%-3.9pp | 0.1%+1.7pp | -1.6%+1.1pp | -2.7%+0.6pp | -3.3%+10.7pp | -13.9%+2.7pp | -16.6% |
| Return on Assets | 1.8%+4.6pp | -2.8%-2.9pp | 0.1%+1.3pp | -1.2%+0.9pp | -2.1%+0.4pp | -2.6%+8.0pp | -10.6%+2.3pp | -12.9% |
| Current Ratio | 4.480.0x | 4.46-0.3x | 4.72-0.6x | 5.32-0.9x | 6.18+0.4x | 5.73+0.8x | 4.88-0.5x | 5.34 |
| Debt-to-Equity | 0.340.0x | 0.340.0x | 0.330.0x | 0.290.0x | 0.270.0x | 0.280.0x | 0.320.0x | 0.29 |
| FCF Margin | -6.5%+14.7pp | -21.2%-34.2pp | 13.0%-4.9pp | 17.9%+23.8pp | -5.9%+5.4pp | -11.3%-12.2pp | 0.9%-12.0pp | 12.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Where Anika Therapeutics Inc Ranks
Frequently Asked Questions
What is Anika Therapeutics Inc's annual revenue?
Anika Therapeutics Inc (ANIK) reported $112.8M in total revenue for fiscal year 2025. This represents a -5.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Anika Therapeutics Inc's revenue growing?
Anika Therapeutics Inc (ANIK) revenue declined by 5.9% year-over-year, from $119.9M to $112.8M in fiscal year 2025.
Is Anika Therapeutics Inc profitable?
No, Anika Therapeutics Inc (ANIK) reported a net income of -$11.0M in fiscal year 2025, with a net profit margin of -9.8%.
What is Anika Therapeutics Inc's EBITDA?
Anika Therapeutics Inc (ANIK) had EBITDA of -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Anika Therapeutics Inc's gross margin?
Anika Therapeutics Inc (ANIK) had a gross margin of 56.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Anika Therapeutics Inc's operating margin?
Anika Therapeutics Inc (ANIK) had an operating margin of -9.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Anika Therapeutics Inc's net profit margin?
Anika Therapeutics Inc (ANIK) had a net profit margin of -9.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Anika Therapeutics Inc's return on equity (ROE)?
Anika Therapeutics Inc (ANIK) has a return on equity of -7.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Anika Therapeutics Inc's free cash flow?
Anika Therapeutics Inc (ANIK) generated $4.4M in free cash flow during fiscal year 2025. This represents a 287.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Anika Therapeutics Inc's operating cash flow?
Anika Therapeutics Inc (ANIK) generated $11.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Anika Therapeutics Inc's total assets?
Anika Therapeutics Inc (ANIK) had $190.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Anika Therapeutics Inc's capital expenditures?
Anika Therapeutics Inc (ANIK) invested $6.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Anika Therapeutics Inc spend on research and development?
Anika Therapeutics Inc (ANIK) invested $25.8M in research and development during fiscal year 2025.
What is Anika Therapeutics Inc's current ratio?
Anika Therapeutics Inc (ANIK) had a current ratio of 4.72 as of fiscal year 2025, which is generally considered healthy.
What is Anika Therapeutics Inc's debt-to-equity ratio?
Anika Therapeutics Inc (ANIK) had a debt-to-equity ratio of 0.33 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Anika Therapeutics Inc's return on assets (ROA)?
Anika Therapeutics Inc (ANIK) had a return on assets of -5.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Anika Therapeutics Inc's Altman Z-Score?
Anika Therapeutics Inc (ANIK) has an Altman Z-Score of 4.98, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Anika Therapeutics Inc's Piotroski F-Score?
Anika Therapeutics Inc (ANIK) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Anika Therapeutics Inc's earnings high quality?
Anika Therapeutics Inc (ANIK) reported a net loss of $11.0M while generating $11.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Anika Therapeutics Inc?
Anika Therapeutics Inc (ANIK) scores 72 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.